XBiotech (XBIT) Short term Debt (2024)

XBiotech (XBIT) posted quarterly Short term Debt of $250000.0 for Q4 2024, down 97.5% quarter-over-quarter from $10.0 million in Q3 2024.

XBiotech (XBIT) Short term Debt (2024) Analysis & Trends

XBiotech's Short term Debt history runs 1 years deep, the most recent figure standing at $250000.0 for Q4 2024.

In Q4 2024, Short term Debt changed N/A year-over-year to $250000.0; the TTM figure through Dec 2024 stood at $250000.0 (changed N/A YoY), while the FY2024 annual figure was $250000.0, changed N/A from the prior year.
Short term Debt for Q4 2024 stood at $250000.0, down from $10.0 million in the prior quarter.
The five-year high for Short term Debt was $10.0 million in Q1 2024, with the low at $250000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	XBiotech	68.90 Mn	68.90 Mn	-

Download Data